← Search & browse all drugs

pralatrexate

L01BA05

Forms & Strengths

Solution for injection: 20 mg/mL, single-dose vial
Lyophilized powder for injection: 20 mg, 40 mg single-dose vials

Adult Dosing

Recommended dose: 30 mg/m^2 administered intravenously over 3-5 minutes once weekly
Dose modification and delay may be required based on toxicity and hematologic recovery

Pediatric Dosing

Safety and efficacy not established in pediatric patients
No dosage recommendations are available for pediatric patients

Indications

Treatment of patients with relapsed or refractory peripheral T-cell lymphoma
Treatment of patients with cutaneous T-cell lymphoma who have progressive, persistent, or recurrent disease

Mechanism of Action

Competitively inhibits dihydrofolate reductase, an enzyme that participates in tetrahydrofolate synthesis
Inhibits DNA synthesis and cell replication, resulting in cell death in sensitive tumor cells

Contraindications

Hypersensitivity to pralatrexate or its components
Severe renal impairment (CrCl <30 mL/min)

Adverse Reactions

Mucositis, thrombocytopenia, anemia, neutropenia, nausea, vomiting, diarrhea, fatigue, pyrexia
Increased risk of infections, including pneumonia and sepsis

Drug Interactions

Concurrent administration with other folate antagonists, nucleoside analogs, may increase toxicity
Decreased renal function may occur with concurrent administration of nephrotoxic agents

Curated Content: Needs Vetting Before Put to Clinical Use